The large size of many disease genes and the multiplicity of mutations complicate the design of an adequate assay for the identification of disease-causing variants. One of the most successful methods for mutation detection is the single strand conformation polymorphism (SSCP) technique. By varying temperature, gel composition, ionic strength and additives, we 
Introduction
The ability to detect mutations or sequence variants in individuals has become increasingly important for the characterisation and screening of disease-causing genes and for linkage analysis of DNA polymorphisms. Different procedures have been designed in recent years to detect small nucleotide changes such as singlebase substitutions, deletions or insertions in polymerase chain reaction (PCR) products. The most commonly used techniques include RNaseA analysis of RNA-DNA heteroduplexes, 1 chemical cleavage of DNA-DNA heteroduplexes, 2 denaturing gradient gel electrophoresis (DGGE), 3 and heteroduplex (HD) analysis. 4 One of the most popular methods for the detection of sequence variants in PCR amplified DNA fragments is SSCP analysis. 5 It is based on the assumption that the electrophoretic mobility of single-stranded DNA in nondenaturing polyacrylamide gels depends not only on its size but also on its sequence-dependent folded structure. A single base change can alter this secondary structure and, in consequence, the electrophoretic mobility of the single strands, resulting in band shifts on the gel. A number of studies have tried to assess or modify factors that can be expected to influence the sensitivity of SSCP analysis, but the procedures described so far are either cumbersome and timeconsuming, requiring 32 P-labelled PCR reactions and gel electrophoresis of 10-24 h followed by autoradiography for 4-12 h, or present different amplification and gel conditions depending on the exon size. [6] [7] [8] [9] Thus a general protocol allowing efficient mutation screening of disease genes is still lacking. The main requirement for an adequate screening technology is that it should be able to accommodate the simultaneous analysis of a large number of amplified samples as well as of many different mutations, it should be non-radioactive, rapid and not require too highly specialised skills.
Here we report on appropriate and uniform PCR and SSCP conditions providing sensitive and efficient mutation screening in any disease-causing gene. The protocol we describe augments 'common' SSCP analysis in terms of simplicity and versatility, combines SSCP and HD analysis increasing the detection rate, allows for greater and very fast sample throughput, and extends the boundaries of amplification product analysis into the 500-600 bp range. To prove the utility and power of the method, we present, as an example, the strategy for the screening of the entire coding region (27 exons) of the CFTR gene, [10] [11] [12] with more than 800 different disease-causing mutations reported so far, and the detection of five new mutations.
Materials and Methods

DNA Samples of Known Mutations
DNA samples of 100 known mutations and polymorphisms used in this study were either obtained by previous analysis of our patients or kindly provided by the authors who first reported these mutations. This group consists of 80 diseasecausing mutations and 20 polymorphisms distributed among the 27 exons of the CFTR gene. The distribution of analysed known mutations is similar to that of the total number of mutations in the entire CFTR gene: missense mutations account for 35% (G27E, G85E, R117H, A120T, I148T, H199Y, R334W, T338I, R347P, R347H, A455E, M718K, S5449N, S5449I, G551D, R560T, R560S, S945L, S977P, I1005R, R1066C, R1070Q, M1101K, D1152H, S1235R, R1283M, N1303K, N1303H), followed by 28% of frameshift mutations (175delC, 394delTT, 457TAT-> G, 905delG, 1078delT, I507, F508, 1609delCA, 1677delTA, 2143delT, 2176insC, 218delA, 2184insA, 2869insG, 3659delC, 3732delA, 3821delT, 3905insT, 4016insT, 4172delGC, 4382delA), 21% of nonsense mutations (Q30X, Q39X, Q220X, W401X, Q525X,  G542X, Q552X, R553X, V569X, E585X, K710X, R792X,  Y1092X, R1162X, S1255X, 
Polymerase Chain Reaction Amplification
The 27 exons (including exon/intron boundaries) as well as intron 19 of the CFTR gene were amplified by the polymerase chain reaction (PCR) 13 17 The following primer sequences were derived from the present study: 
SSCP Analysis
Three microliters of the amplification product were added to 2-3 µl of SSCP buffer (95% formamide, 100 mM NaOH, 0.25% bromphenol blue, 0.25% xylencyanol) and denatured at 95°C for 2 min followed by rapid cooling on ice. Three microliters of the mixture were loaded on to a 12% nondenaturing polyacrylamide gel (99% acrylamide, 1% piperazine diacrylamide (PDA)) cast on to GelBond (Bioconcept, Allschwil, BL, Switzerland). The mix for one gel of 220 ϫ 118 ϫ 0.5 mm was: 5.3 ml 40% acrylamide-PDA solution, 8.5 ml Tris-formate buffer (0.75 M, pH 9.0), 3 ml glycerol (41%), 240 µl ammonium persulfate (APS) 10%, and 24 µl TEMED. The trailing ion, contained in soaked blotting-paper strips (Schleicher & Schuell, Feldbach, ZH, Switzerland) was Tris-borate buffer (pH 9.0). Bromphenol blue was added to the electrode buffer to serve as a dye marker for the discontinuous buffer boundary. Electrophoresis was performed using a Pharmacia LKP 2117 Multiphor II Electrophoresis Unit at 350 V for 90 min (12-15°C). Up to 40 samples can be run on one gel. The SSCP and HD banding patterns were detected by the silver staining method described by Budowle et al.
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DNA Sequence Analysis
Ten microliters of the purified samples of double-stranded PCR products showing aberrant banding patterns following SSCP/HD analysis were subjected to the cycle sequencing method with Taq polymerase for the incorporation of fluorescent-labelled dideoxynucleotides. Sequencing reactions were resolved on an ABI 373A sequencing system (Perkin Elmer, Foster City, CA, USA) and the electrophoretograms were compared using the SEQED software package from the manufacturer. All samples were sequenced in both directions or amplified and sequenced twice for confirmation using the same primers as those for PCR-SSCP analysis with a few exceptions where we used internal primers.
Internal primers used for sequence analysis:
Results
Mutation Detection Rate
In order to determine the sensitivity and utility of the modified SSCP/HD method for mutation detection in the CFTR gene, a total of 100 known variants (80 disease causing mutations and 20 polymorphisms) in the CFTR gene was analysed. Intron 19, all 27 exons and their exon-intron boundaries, including the 24 most common mutations worldwide (G85E, R117H, 621 + 1G-> T, 711 + 1G-> T, 1078delT, R334W, R347P, A455E, I507, F508, 1717-1G-> A, G542X, S549N, G551D, R553X, R560T, 1898 + 1G-> A, 2184delA, 2789 + 5G-> A, R1162X, 3659delC, 3849 + 10kbC-> T, W1282X, N1303K) (Cystic Fibrosis Genetic Analysis Consortium 1994), and the 15 most common mutations in our population (I148T, 1078delT, R334W, R347P, F508, 1717-1G-> A, G542X, R553X, 2347delG, D1152H, R1162X, 3849 + 10kbC-> T, 3905insT, W1282X, N1303K), were considered in this study. Figure 1 shows SSCP/HD analyses of 11 DNA samples from one healthy control and 10 CF patients known to contain one or two exon 10 mutations or polymorphisms. All nine genotypes tested can be distinguished from each other on this gel without restriction digest of the 491 bp amplification product, as each variant displays a unique HD pattern. Figure 2 demonstrates a mutation screening of exon 11 after restriction enzyme digestion using Hind II. Six different mutations and 8 different genotypes are tested and easily detectable by their specific SSCP pattern. The sensitivity of our SSCP/ HD analysis conditions for the detection of CF mutations is presented in Table 1 . The R792X nonsense mutation in exon 13 and the 4374 + 1G-> T splice site mutation in exon 23 were not detectable with our screening method, whereas 78 out of 80 mutations and all 20 polymorphisms showed band shifts either in the single or in the double strands of the amplified DNA fragments. Three mutations (R1066C, M1101K, E1371X) could only be identified after restriction enzyme digestion of the amplification product, and five mutations (711 + 1G-> T, R347H, T338I, Y1092X, S1255X) were discovered in the uncut, but not in the digested, PCR product. All fragments presenting with abnormal band patterns were directly sequenced and all mutations could be identified and confirmed. Based on our findings and on the fact that there is no random distribution of mutations within the CFTR gene we developed a mutation screening strategy using our SSCP conditions that allows in three stages and within one week analysis of the entire coding region and, in consequence, the detection of variants and their identification as polymorphisms or as disease-causing mutations ( Figure 3 ).
Identification of Previously Unknown Mutations in CF Patients Analysed for Investigation Purposes
Using this newly developed strategy in routine diagnostic analyses, we screened 198 patients (396 chromosomes) at high risk for CF, who had been sent to our CF centre and were of various nationality. Our mutation screening system detected 41 different known mutations in 381 chromosomes (Table 2 ) including at least 20 common and/or population-specific mutations. Moreover, we identified the following five novel mutations in six chromosomes ( Figure 4 ):
1. 420del9 An inframe deletion of nine bases (GTA CAG CCT) after nucleotide 420 situated in exon 4 and resulting in the loss of the three aminoacids Val97, Gln98, and Pro99.
2. 1199delG A frameshift deletion of one base (G) after nucleotide 1199 in exon 7 leading to a stop codon seven codons downstream.
R560S
A transversion A-> T at nucleotide position 1812 located in exon 12 leading to the exchange of the amino acid Arg by a Ser.
4. A613T A transversion G-> A at nucleotide position 1969 located in exon 13 leading to the exchange of the amino acid Ala by a Thr.
T1299I
A transversion C-> T at nucleotide position 4028 located in exon 21 leading to the exchange of the amino acid Thr by a Ile.
In nine patients we found only one mutation, the second mutation being not detectable by our screening system.
Discussion
Mutation detection is one of the most important areas of molecular biology today playing two fundamental roles in gene discovery. Initially it serves to identify polymorphisms for refining linkage analysis in the chromosomal region of interest and furthermore it makes the characterisation of disease-causing genes possible. Searching for point mutations in a large gene,
Figure 2 SSCP analysis of CF mutations in exon 11 of the CFTR gene after digestion with HindII. The slots C present wild type (wt) sequences, 1-8 present amplification products from CF patients with the following genotypes: 1 = R553X/R553X; 2 = 1717-1G-> A/wt; 3 = R553X/wt; 4 = G542X/wt; 5 = G542X/1717-1G-> A; 6 = G551D/wt; 7 = R560T/wt; 8 = S549N/wt.
General protocol for point mutation screening S Liechti-Gallati et al t such as the CFTR gene that consists of 27 exons in which a heterogeneous mutation spectrum ( > 800) is expected, is an enormous task. Ideally, an optimal technique for mutation detection in such a gene has to be fast, must enable the screening of large stretches of DNA with high sensitivity and specificity, would not require toxic or dangerous compounds, and would provide information about the location of the mutation. SSCP combined with HD analysis holds promise as being such a technique. However, the most fundamental question of any method used for genetic analysis is its sensitivity. Important factors that could play a role in the sensitivity of SSCP analysis include the nature of the mutation and the sequence composition of the DNA fragment as well as the locus of the mutation within the amplification product and the influence of the neighbouring bases. For SSCP there is no theoretical model for predicting the three-dimensional structure and/or mobility shift of single-stranded DNA. On the other hand, it is well known that conformational changes of a single-stranded molecule being induced by a mutation are very sensitive to environmental influences such as temperature, gel composition, ionic strength, and additives. Thus, varying these parameters, we optimised the sensitivity of SSCP not only for a given fragment but for all 27 exons of the CFTR gene. We defined SSCP conditions, such as 12% nondenaturing polyacrylamide gel, 7% glycerol, two-phase buffer system, 90 min electrophoresis at 12-15°C, silver staining, that can be used for mutation screening in any other human disease-causing gene. The use of a discontinuous electrophoresis system allows concentration of the single-stranded species in the samples into a very small volume, thus additionally increasing the resolution of the polyacrylamide gel. Gels from completed SSCP Taq I  0+1  100  100  14b  449  Ssp I  1+0  100  100  15  485  Taq I  2+2  100  100  16  570  Sau 3A  1+1  100  100  17a  302  Sau 3A  2+1  100  100  17b  463  Hind II  5+0  60  80  18  451  Alu I  1+0  100  100  19  454  Bgl II  8+2  100  100  20  473  Hae III  4+1  100  80  21  405  Bam HI  3+1  100  100  22  562  Hind II  2+0  50  100  23  400  Xba I  1+1  50  50  24  359  Hind II  1+1  100  100 analysis can be conveniently stored in plastic wrap at room temperature for several months without detectable diffusion of the band pattern. We collected DNA samples containing 100 different mutations and polymorphisms which are distributed along the gene. In total, 27 exons together with their exon/intron boundaries plus intron 19 have been considered. The number of variants analysed within each region ranges from 1 to ten because of the uneven distribution of mutational events. With the conditions described here 100% of the polymorphisms and 97.5% of the mutations were detectable including the 24 most common mutations worldwide. The use of fragments longer than 300 bp (optimal size for SSCP analysis 19, 20 ) in our SSCP analysis does not seem to be a disadvantage in identifying point mutations. Even the largest fragment used in this screening (exon 16, 570 bp) gave rise to the identification of a base substitution (T-> C, S977P) without digestion of the amplification product before SSCP analysis. The reason why particular mutations can only be identified with, or without, digestion of the PCR product may be based on the fact that digestion alters the position of the mutation within the amplification product and in consequence also the conformation of the single-strand resulting or not in a band shift. In addition, during the 90 min SSCP electrophoresis, denatured and partly reannealed DNA fragments remain on the gel allowing the detection of heteroduplex formations (Figures 1, 2, 4) . Thus SSCP and heteroduplex analysis can be simultaneously performed on the same gel increasing the sensitivity of both methods.
Despite the improved sensitivity of our PCR-SSCP analysis, false negatives cannot be excluded by this technique. As the nature and location of a base substitution as well as the base sequence around a point mutation have also an effect on the mobility shift of single strands, some mutations may not be detected even not under ideal conditions of electrophoresis. Moreover, intronic mutations, creating cryptic or new splice sites as well as large deletions or insertions spanning one or more exons are missed using this technique. Therefore, absence of mutation cannot be proven for certain. False positives can also appear as a result of the annealing of free oligonucleotides to PCR product strands leading to mobility shifts. This problem General protocol for point mutation screening S Liechti-Gallati et al t can be avoided by minimising the primer concentration to less than 25 pmol/50 µl reaction volume or by removing oligonucleotides prior to SSCP analysis.
Within those limitations discussed above, the assay that we have described offers several advantages over current techniques. 21, 22, 23 Reaction conditions are identical for all DNA fragments recognising all classes of point mutations (base substitutions, deletions, insertions). The assay provides rapid (at least 4 gels-= 160 samples per day) and efficient screening and characterisation of mutations using a modified SSCP analysis followed by direct fluorescent automated sequencing of the variable amplification product. The technique developed demonstrates excellent singlestrand separation and non-radioactive visualisation on polyacrylamide gels, and is time-saving and directly I14b  002  Italian  Spanish  D1152H  E18  002  Swiss, French  4016insT  E21  002  Turkish  Q39X  E02  001  Swiss  394delTT  E03  001  Swiss  Nordic, Finnish  R117H  E04  001  Swiss  A120T  E04  001  Swiss  G126D  E04  001  Swiss  711+5G->A  I05  001  Russian  M348K  E07  001  Italian  L568F  E12  001  Italian  2183AA->G  E13  001  Italian  Italian  K710X  E13  001  Swiss  S945L  E15  001  French  3272-26A.->G  I17a  001  Swiss  M1101K  E17b  001  Swiss  Huttite  3601-17C->T  I18  001  Swiss  R1158X  E19  001  Swiss  4005+1G-A  I20  001  Italian applicable to early diagnostic testing, carrier detection and prenatal diagnosis. The screening strategy presented allows analysis of seven exons within 5 hours and analysis of the entire coding region of the CFTR gene within 1 week, including sequence analysis of the variants. Moreover, we did not experience any falsepositive findings, and the detection of known mutations was not affected by either the nature or context of the mutation. The ability of this technique to detect mutations independent of their nature, frequency, and population specificity was confirmed by the identification of five previously unknown mutant alleles in Swiss CF patients as well as by the detection of 41 different mutations in 198 patients analysed investigatively ( Table 2 ). In 1997 and 1998 we participated successfully in the ECCACF quality control trials using our screening technique.
Additionally, our protocol represents a general model for point mutation analysis in other genetic disorders and has already been successfully established for OTC deficiency, 24 collagen deficiency, 25 X-linked myotubular myopathy (XLMTM), 26 Duchenne and Becker muscular dystrophy (DMD, BMD), Wilson disease (WD), neurofibromatosis I and II, CharcotMarie-Tooth disease, hereditary neuropathy with liability to pressure palsies, and defects in mitochondrial DNA. 27 As soon as the MTM1 gene was identified we screened 47 unrelated XLMTM patients using the SSCP conditions described in Materials and Methods and found 34 novel and six known mutations. 28 Analysing 23 WD patients we detected 10 known and eight novel mutations, and in 38 patients at risk for mitochondrial diseases we identified three novel and seven known mutations as well as many polymorphisms. No other protocol published so far presents standard SSCP/HD conditions for mutation screening in different disease genes.
In conclusion, our study provides firm evidence that this modified SSCP/HD technique is very fast and has the ability to detect at least 97% of all point mutations in the coding region of a disease gene. Thus, we consider it to be a high yield scanning method that can be recommended to laboratories involved in the mutation screening of genetically heterogeneous populations. General protocol for point mutation screening S Liechti-Gallati et al t 597
